Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Orthopoxvirus VP37 envelope wrapping protein, also known as P37 or F13 (gene F13L in vaccinia virus), is a highly conserved viral protein found in all members of the orthopoxvirus genus, including variola (smallpox), monkeypox, cowpox, and vaccinia viruses. It is essential for the formation of the viral envelope that allows mature virions to exit infected cells and spread within the host. VP37 mediates envelopment of intracellular mature virus (IMV) particles, requiring interaction with host cell proteins Rab9 GTPase and TIP47 for virion egress. Tecovirimat is an FDA-approved antiviral drug that specifically targets VP37, blocking its interaction with Rab9/TIP47 and preventing viral spread.
Tecovirimat targets and inhibits the activity of the orthopoxvirus VP37 protein...blocks its interaction with cellular Rab9 GTPase and TIP47...prevents formation of egress‑competent enveloped virions necessary for cell‑to‑cell...dissemination
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Orthopoxvirus VP37 envelope wrapping protein (VP37).